최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0650059 (2007-01-04) |
등록번호 | US-8158670 (2012-04-17) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 580 |
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
1. A method for maintaining vessel luminal area following vascular trauma, comprising: administering to a mammal an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises
1. A method for maintaining vessel luminal area following vascular trauma, comprising: administering to a mammal an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount that has a minimal effect on protein synthesis and allows for vascular repair. 2. The method of claim 1, wherein the sustained release dosage form comprises biodegradable microparticles, biodegradable nanoparticles or a mixture thereof. 3. The method of claim 1, wherein the sustained release dosage form comprises a cytoskeletal inhibitor. 4. The method of claim 1, wherein the sustained release dosage form comprises a cytochalasin or a cytochalasin analog. 5. The method of claim 1, wherein the sustained release dosage form comprises taxol or a taxol analog. 6. The method of claim 1, wherein the cytostatic amount of the sustained release dosage form does not exhibit substantial cytotoxicity. 7. The method of claim 1, wherein the administration inhibits vessel stenosis or restenosis. 8. The method of claim 1, wherein the administration is local. 9. A method for maintaining vessel luminal area, comprising: administering to a mammalian vessel an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount which allows for cellular repair and extracellular matrix production. 10. The method of claim 9, wherein the sustained release dosage form comprises biodegradable microparticles, biodegradable nanoparticles or a mixture thereof. 11. The method of claim 9, wherein the sustained release dosage form comprises a cytoskeletal inhibitor. 12. The method of claim 9, wherein the sustained release dosage form comprises a cytochalasin or a cytochalasin analog. 13. The method of claim 9, wherein the sustained release dosage form comprises taxol or a taxol analog. 14. The method of claim 9, wherein the cytostatic amount of the sustained release dosage form does not exhibit substantial cytotoxicity. 15. The method of claim 9, wherein the administration inhibits vessel stenosis or restenosis. 16. The method of claim 9, wherein the administration is local. 17. A method for maintaining vessel luminal area, comprising: administering to a mammalian vessel an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount which allows for cellular repair and extracellular matrix production, wherein the dosage form comprises a cytochalasin or a cytochalasin analog.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.